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Rebecca L Thorne, Qingsheng Zhang and Jimmy Chun Yu LouieAbstract
Background: There is some evidence in the literature that emphasising fish consumption may assist with weight
loss. The aim was to assess the effects of advice to consume 2 fish meals per week in a weight loss diet.
Methods: A parallel randomised placebo-controlled trial was conducted in 118 obese Australian adults
(mean BMI ± SD 31.3 ± 3.5 kg/m2; mean age ± SD 45 ± 10 y; 28% male). Participants received low calorie dietary
advice + placebo (1 g olive oil; Control), low calorie dietary advice emphasising fish + placebo (Fish), or low calorie
dietary advice emphasising fish diet + LCn3PUFA supplements (Fish + S). Individualised advice targeted 2 MJ energy
deficit (30%E fat, 45%E carbohydrate and 25%E protein) with or without two servings (180 g) fatty fish/wk.
Results: All groups lost weight at 12 months (Control −4.5 kg vs. Fish −4.3 kg vs. Fish + S −3.3 kg; p < 0.001) and
percentage body fat (Control: -1.5% vs. Fish: -1.4% vs. Fish + S: -0.7%; p < 0.001) but there were no significant
differences between groups. Cardiovascular disease risk factors changed as expected from weight loss.
Conclusions: Advice to consume 2 fish meals per week did not enhance the effects on weight loss of a healthy
low calorie diet.
Trial registration: ACTRN12608000425392.
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Dietary guidance draws on evidence of health effects from
foods, nutrients and whole diets [1,2], yet that these are all
inter-related. There are calls for a greater emphasis on
food in the construction of dietary guidelines [3] and this
has implications for nutrition research, particularly with
the concurrent need to address the obesity problem.
Weight management reflects total energy intake which is
delivered by the whole diet. Evidence for differential
effects of single foods may be difficult to demonstrate
when total dietary energy is kept below requirements. In
addition, trial participants may choose foods and dietary
patterns that are not fully compliant with the treatment,
and in many cases the results reflect effects of dietary
advice strategies, not of the foods, diets or nutrients* Correspondence: ltapsell@uow.edu.au
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© 2013 Tapsell et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortargeted, (for example see [4]). Nevertheless, evidence
based statements can be found drawing on literature that
shows effects and associations between food intakes and
health outcomes including weight management [5].
LCn3PUFA is an example of a key nutrient that has
been implicated in weight loss. Observational studies
show a relationship between LCn3PUFA status and a
healthier BMI [6], and body composition [7]. Small,
short term experimental studies show that a dose of
1.8 g LCn3PUFA /day can preferentially decrease adi-
posity [8] and increase fat oxidation [9]. This research
suggests plausible mechanisms of nutrient action, but
this research has not translated to consistent clinical
outcomes. One study has shown that doses of around
3 g LCn3PUFA /day can enhance weight loss [10] but
others testing the same dose [11] or as 1.4% energy [12]
have not found no effect. From a food perspective, LCn3
PUFA are primarily found in fish, so further researchLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formative. One short term study found that eating oily
fish or taking supplements may be equally beneficial in
achieving a greater weight loss, at least in fish eating
populations [13].
Mechanistic and short term studies provide evidence
at a proof of concept level [14], but for dietary guidance,
weight loss maintenance is the major health goal. Long
term dietary trials are difficult to conduct and a loss to
follow up can be expected [15] with publications show-
ing a range of reporting [16]. In addition, translating the
concept from mechanistic and short term studies also
means testing an appropriate amount of food and/or
supplements which might align with current recommen-
dations. In terms of LCn3PUFA and fish, this is about
600 mg LCn3PUFA or 2 fish meals/week [17]. The aim
of the study reported here was to assess the effects on
long term weight loss of advice to consume low calorie
diets emphasising 2 fish meals per week with or without
active supplements delivering equivalent amounts of
LCn3PUFA.
Methods
Study design
A 12 month randomised controlled trial was conducted
between 2009–2010 with overweight adults in three
parallel diet advice arms: low calorie + placebo (control);
low calorie + fish + placebo (Fish); and low calorie + fish +
eicosapentaenoic acid (EPA)/docosahexanoic acid (DHA)
supplements (Fish + S). The second intervention arm
served as an enhancement strategy in case of poor compli-
ance to fatty fish consumption over the year. The primary
outcomes were change in body weight, BMI and percent-
age body fat. Secondary outcomes included change in
cardiovascular disease risk factors. Recruitment was
by media advertisements and emails sent by the re-
search team throughout Wollongong, a major coastal
city 70 km south of Sydney, Australia. This study was
conducted according to Declaration of Helsinki guide-
lines and procedures were approved by the University
of Wollongong Human Research Ethics Committee.
Written informed consent was obtained from all par-
ticipants. This trial is registered at http://www.anzctr.
org.au (ID: ACTRN12608000425392).
Randomisation and blinding
A researcher independent of the subject interface under-
took the randomisation of participants into diet groups
(stratified by sex and block randomised; nQuery Advisor
V 7.0, Statistical solutions, Cork, Ireland) and the code
was kept from the researchers collecting dietary data
and delivering treatment. Supplements were coded off-
site. Different dietitians collected dietary data and
provided dietary advice. Those providing advice werenecessarily aware of diet category but not of supplement
allocation.
Participants
The study sample comprised middle aged (mean ± SD
age 45 ± 10 y) obese adults (mean ± SD BMI 31.3 ±
3.5 kg/m2). Inclusion criteria included: age between 18
to 60 years, BMI between 25 to 37 kg/m2, waist circum-
ference > 94 cm (men) or > 80 cm (women), otherwise
healthy. Individuals with major illnesses, diabetes melli-
tus, LDL ≥ 6 mmol/L, food allergies or habits inhibiting
compliance, low literacy, inadequate conversational
English, and those who are already taking fish oil
supplements, unable to undertake study requirements,
pregnant/lactating, not weight stable (within 3 kg) in the
past 6 months or on a weight-loss diet were excluded
from participation. Participants were not paid.
Dietary intervention
The intervention addressed dietary intake at the, food
(fish), key nutrient (LCn3PUFA) and whole diet (low
calorie) level. The fatty fish target and LCn3PUFA
equivalent reference value were based on materials in
the Nutrient Reference Values (NRVs) report for
Australia and New Zealand [17]. These suggested two
servings (180 g) of fatty fish per week and a dietary
intake for LCn3 PUFA based on the 90th percentile of
population consumption levels (i.e. 610 mg/day for men
and 430 mg/day for women) [17]. All groups were
advised on a hypocaloric diet (2 MJ energy below
estimated energy requirements estimated by the Mifflin
equation [18] with 1.25 physical activity factor), targeting
25% energy from protein, 45% energy from carbohydrate
and 30% energy from fat. Diets referred to low fat staple
foods (fruit, vegetables, cereals, lean meat, low fat
milk and yoghurt) and small amounts of nuts, seeds,
spreads and oils. Food groups were congruent with
the Australian Guide to Healthy Eating [19], and
formed the basis of the standardised procedure for
both diet groups and the template of the diets sheets.
Participants in the Fish and Fish + S advice groups
were specifically encouraged to consume 180 g fatty
fish per week. Participants in the control group were
not given specific advice regarding fish intake, but
were instructed to consume prescribed amounts of foods
rich in protein, of which fish was an option. Dietary
education was supported by print resources outlining
methods of cooking the appropriate fish and recipes. The
Control and Fish groups were given placebo capsules (1 g
olive oil per day) and the Fish + S group the active supple-
ments (420 mg EPA + 210 mg DHA; Blackmore’s Promega
Heart, Blackmores Australia). Dietary education (1 hour)
and follow-up (30 min) with one of seven experienced
dietitians was provided at 0, 1, 2, 3, 6, 9, and 12 months
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compliance. Accredited Practising Dietitians collected
dietary data at 0, 3 and 12 months via a validated diet
history interview (DH) [20]. Dietary data was analysed
using the FoodWorks software system (Version 6, 2009,
Xyris Software, Spring Hill, QLD, Australia). Reported
food intake data was converted to intakes of energy and
macronutrients using the AUSNUT1999 [21] and
AusFood2001 databases (revision 11, from FoodWorks
2009 version 6, Xyris Software, Spring Hill, QLD,
Australia). Reported LCn3PUFA intakes were assessed
separately using the AUSNUT2007 database [22]. The
percentage fish in each dish or product was calculated
based on a validated approximation of canned fish labels
[23] and standardized recipe data. Habitual physical
activity at baseline and 12 months was assessed by
questionnaire [24]. Advice was given to all groups to walk
for 30 minutes three days per week.
Measurement of anthropometric and biochemical
variables
Height was measured using a stadiometer without shoes.
Body weight was measured in an upright position in
minimal clothing, without shoes using digital scales withControl
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were analysed at Australian Research Laboratories
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Figure 2 Fish consumption at baseline, 3 months and 12 months.
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Compliance to fish and supplement recommendations
was calculated for all participants who remained in the
trial at 12 months. In order to calculate compliance to
fish recommendations, an average of each participant’s
fish intake from all available diet histories was taken, as
described by Alhassan et al [28]. Compliers were defined
as consuming < 180 g fish/week for the control group,
consuming ≥ 180 g fish/week for the Fish group, and
either consuming ≥ 180 g fish/week or taking ≥ 90% of
the supplements in the Fish + S group.
Power calculations
Using data from a previous study [29] and an expected
weight change of −2.6 kg in the control and −4.7 kg inTable 1 Subject characteristics at baseline
Variable All subjects who has
baseline data
Completers
n 118 63
Age (years) 45.1 ± 8.4 45.4 ± 9.2
Male (%) 26.3 31.7
Weight (kg) 88.6 ± 12.1 88.5 ± 12.5
BMI (kg/m2) 31.2 ± 3.5 30.9 ± 3.6
Smokers (%) 5.9 6.3
Education level TAFE or above (%) 64.4 68.3
Labour intensive job (%)1 35.0 33.3
Taking regular medication (%) 26.3 20.6
Country of birth (%)
Oceania 83.6 87.1
Europe 12.1 9.7
Others 4.3 3.2
Values are mean ± SD or percentages. p values obtained using ANOVA for continuo
#p value for differences between completers and dropouts.
*p value for differences between compliers and non-compliers.
1Labour intensive jobs included: carer, home duties, retail and trade professionals.the intervention groups, we required 27 participants in
each group to achieve statistical significance (α = 0.05,
β = 0.9). As shown in Figure 1, we enrolled 126 people,
from an initial pool of 374 volunteers. Eight participants
withdrew from the study before treatment so their data
were excluded from all analyses.
Statistical analysis
All statistical analyses were performed using IBM SPSS
(version 17.0 and 19.0, IBM Australia, Lane Cove, NSW,
Australia). Analysis of the primary outcome (i.e. weight)
was performed on an intention to treat basis with the
118 participants who provided baseline data, using a
linear mixed model. Several approaches were taken to
investigate the effect of missing data on the primaryDropouts p value# Compliers Non-compliers p value*
55 - 36 27 -
44.9 ± 7.4 0.751 47.1 ± 8.3 43.1 ± 10.0 0.092
20.0 0.148 30.6 33.3 0.815
88.7 ± 11.6 0.921 89.5 ± 12.2 87.1 ± 13.1 0.444
31.6 ± 3.4 0.302 31.6 ± 3.5 29.9 ± 3.5 0.069
5.5 0.837 8.3 3.7 0.456
60.0 0.350 55.6 85.2 0.012
37.0 0.713 36.1 29.6 0.359
32.7 0.137 22.2 18.5 0.719
79.6 85.7 88.9
14.8 0.552 11.4 7.4 0.858
5.6 2.9 3.7
us variables and Pearson’s Chi’s square for categorical variables.
Table 2 Weight of participants at baseline, 3 months and 12 months
Control Fish Fish + S p values
Baseline 3 months 12 months Baseline 3 months 12 months Baseline 3 months 12 months Time Group Interaction
Mixed model with all available data only
n 39 29 18 39 30 25 40 28 20 - - -
Mean ± SD 88.5 ± 12.7 84.2 ± 12.6 81.7 ± 14.1 90.0 ± 12.2 84.8 ± 12.3 80.9 ± 12.7 88.5 ± 11.4 82.9 ± 11.7 84.3 ± 11.7 < 0.001 0.682 0.326
< 0.001‡ 0.617‡ 0.338‡
Mixed model with missing values imputed
n 39 39 39 39 39 39 40 40 40 - - -
Mean ± SD 88.5 ± 12.7 83.7 ± 12.0 82.9 ± 13.0 90.0 ± 12.2 86.0 ± 12.3 84.7 ± 13.2 88.5 ± 11.4 83.8 ± 11.3 83.7 ± 11.3 < 0.001 0.767 0.803
LOCF#
n 39 39 39 39 39 39 40 40 40 - - -
Mean ± SD 88.5 ± 12.7 84.6 ± 12.1 83.9 ± 12.7 90.0 ± 12.2 86.7 ± 12.8 85.7 ± 13.6 88.5 ± 11.4 85.2 ± 11.5 85.3 ± 11.7 < 0.001 0.805 0.457
BOCF#
n 39 39 39 39 39 39 40 40 40 - - -
Mean ± SD 88.5 ± 12.7 84.6 ± 12.1 84.8 ± 13.1 90.0 ± 12.2 86.7 ± 12.8 86.0 ± 14.0 88.5 ± 11.4 85.2 ± 11.5 86.0 ± 11.2 < 0.001 0.840 0.348
Completers only#
n 18 18 18 25 25 25 20 20 20 - - -
Mean ± SD 89.5 ± 13.9 83.2 ± 13.0 81.7 ± 14.1 87.1 ± 11.8 82.5 ± 11.8 80.9 ± 12.7 89.4 ± 12.3 84.2 ± 11.4 84.3 ± 11.7 < 0.001 0.799 0.141
‡Adjusted for omega-3 index (red blood cell EPA + DHA).
#p value calculated by repeated measures analysis of variance based on data from five time points (0, 3, 6, 9 and 12 months).
LOCF last observation carried forward; BOCF baseline observation carried forward.
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PROC MI in SAS V9.2, SAS Inc. Cary, NC), last obser-
vation carried forward (LOCF), and baseline observation
carried forward (BOCF). These methods are the most
commonly used in weight loss studies [30]. Completers
only (n = 63) analyses were also performed.
Secondary outcomes were analysed using linear mixed
model, using data on all participants. Covariates were
included in the models where biologically appropriate,
as noted in the results section. Intra-class correlations
and chi square analyses were used to examine any
potential therapist effect, and none was noted. Statistical
significance was set at p < 0.05.
Results
After the 3 month intensive phase n = 87 participants
remained in the study and at the 12 month follow up
data was available for n = 64 (weight data missing for
n = 1). Reasons for attrition are shown in Figure 1. Of
the 12 mo completers, 57% were judged to be compliant,
39% (n = 7) for the control group who reported <180 g
fish/week, 48% (n = 12) for the Fish group who re-
ported ≥180 g fish/week, and 85% (n = 17) for the Fish + S
group who reported ≥180 g fish/week or ≥90% sup-
plements. Actual fish consumption was highly variable
(Figure 2). There was no difference between groups in
dropout rates (log ‘rank test, p = 0.872), and the character-
istics of participants who withdrew were similar to the
completers (Table 1). There were no adverse events, and
no changes in medications. Prior to randomization, partic-
ipants reported plausible usual dietary intakes for the
study population, including a median intake of 370 mg
(men) and 290 mg (women) LCn3PUFA per day, more
than half that of the suggested dietary targets (610 mg/day
for men and 430 mg/day for women). Physical activity
scores increased over 12 month, with no significant differ-
ence between groups (One-way ANOVA, p = 0.673).Figure 3 Change in % body weight by group at 3 and 12 months.Effects on weight loss and body fat
In the intention to treat analysis (Table 2) based on the
linear mixed model, all groups lost weight at 12 months
(Control −4.5 kg vs. Fish −4.3 kg vs. Fish + S −3.3 kg;
p < 0.001) and percentage body fat significantly decreased
(Control: -1.5% vs. Fish: -1.4% vs. Fish + S: -0.7%; p < 0.001).
There were no significant differences between groups for
these variables and this result remained after adjustment
for EPA +DHA status (Figure 3). All other methods of
analysis for the primary outcome similarly showed a sig-
nificant time effect, with no significant group differences,
and restricting the analysis to completers only did not
significantly change the results. After stratifying the
analysis based on compliance, there was no significant
weight loss among non-compliers regardless of dietary
assignment (time effect = 0.653; group effect = 0.371; inter-
action = 0.972). Significant weight loss was observed
among compliers (87.7 kg at baseline vs. 79.7 kg at
12 months; time effect = 0.034); but there was no differ-
ence between groups (group effect = 0.299; interaction =
0.996). The mean weight loss at three months was greater
in those who completed the 12 months than those who
did not (−5.2 vs. -3.2 P = 0.005).
Effects on cardiovascular disease risk factors and biomarkers
All groups showed improvements in fasting insulin,
HOMA-IR and triglycerides (Table 3). Systolic blood
pressure, fasting glucose, total cholesterol and leptin
levels decreased for the entire study sample, with no dif-
ference between groups. There was a significant time by
group interaction for self-reported intake of LCn3PUFA
(Table 4, p = 0.034), confirmed by a significant group
difference in erythrocyte omega-3 index (Table 3,
p = 0.009). This effect was primarily due to changes in
the Fish + S group, and post hoc analysis revealed a sig-
nificant difference between the Fish and Fish + S groups
(Fish: 3.4 ± 1.0% vs. Fish + S: 4.4 ± 1.6%; p = 0.007).
Table 3 Body mass index, % body fat and clinical assessments at baseline, 3 months and 12 months
Variable Control Fish Fish + S Difference between groups
n Value n Value n Value Effect p value*
Body mass index (kg/m2)†
Baseline 39 30.9 ± 3.5 39 31.4 ± 3.6 40 31.6 ± 3.4 Time < 0.001
3 months 29 29.3 ± 3.4 30 29.5 ± 3.6 28 29.6 ± 3.1 Group 0.376
12 months 18 28.0 ± 3.6 25 28.2 ± 3.4 20 29.8 ± 3.5 Interaction 0.370
Body fat (%)†#
Baseline 34 36.7 ± 7.3 36 38.0 ± 7.5 36 36.0 ± 8.7 Time < 0.001
3 months 21 33.4 ± 7.7 25 35.5 ± 7.6 20 33.0 ± 10.3 Group 0.595
12 months 14 34.4 ± 7.6 16 37.4 ± 8.1 16 34.0 ± 10.2 Interaction 0.369
Fasting glucose level (mmol/L)†
Baseline 37 5.0 ± 0.5 39 5.1 ± 0.5 39 5.0 ± 0.6 Time 0.009
3 months 27 4.9 ± 0.5 30 5.0 ± 0.6 28 4.7 ± 0.6 Group 0.585
12 months 17 5.1 ± 0.4 24 4.9 ± 0.7 21 4.8 ± 0.4 Interaction 0.350
Fasting insulin level (mU/L)†‡
Baseline 37 9.1 (7.7 – 12.9) 39 9.6 (7.4 – 13.8) 39 12.0 (8.5 – 17.0) Time 0.001
3 months 27 8.7 (7.1 – 11.5) 29 9.1 (7.4 – 12.2) 28 10.4 (7.2 – 13.0) Group 0.360
12 months 18 8.5 (6.3 – 10.5) 24 8.2 (6.2 – 11.1) 21 9.2 (6.5 – 13.1) Interaction 0.086
Fasting total cholesterol (mmol/L)†
Baseline 37 5.3 ± 1.2 39 5.3 ± 0.8 39 5.2 ± 0.9 Time < 0.001
3 months 27 4.8 ± 0.8 30 5.0 ± 0.8 28 5.1 ± 0.9 Group 0.309
12 months 18 4.6 ± 0.7 24 5.2 ± 1.0 21 5.4 ± 0.9 Interaction 0.098
Fasting triglycerides (mmol/L)†‡
Baseline 37 1.4 (0.9 – 2.0) 39 1.3 (1.0 – 1.8) 39 1.3 (1.0 – 2.1) Time < 0.001
3 months 27 1.3 (0.9 – 1.6) 30 1.3 (1.0 – 1.5) 28 1.1 (0.7 – 1.7) Group 0.661
12 months 18 1.0 (0.7 – 1.5) 24 1.1 (0.9 – 1.4) 21 1.0 (0.6 – 1.5) Interaction 0.122
Fasting HDL cholesterol (mmol/L)†
Baseline 37 1.5 ± 0.4 39 1.5 ± 0.4 39 1.4 ± 0.4 Time < 0.001
3 months 27 1.5 ± 0.3 30 1.4 ± 0.3 28 1.4 ± 0.5 Group 0.566
12 months 18 1.4 ± 0.3 24 1.4 ± 0.4 21 1.5 ± 0.4 Interaction 0.739
Fasting LDL cholesterol (mmol/L)†
Baseline 37 3.1 ± 1.1 39 3.1 ± 0.8 38 3.1 ± 0.8 Time 0.001
3 months 27 2.7 ± 0.8 30 3.0 ± 0.8 28 3.1 ± 0.7 Group 0.242
12 months 18 2.7 ± 0.8 24 3.2 ± 0.9 21 3.4 ± 0.9 Interaction 0.091
Fasting leptin (mg/mL)¶‡
Baseline 37 21.5 (11.7 – 31.3) 38 19.9 (12.3 – 29.6) 39 18.0 (10.4 – 30.9) Time < 0.001
3 months 27 11.8 (7.2 – 20.5) 30 14.7 (7.2 – 20.8) 28 14.1 (7.0 – 22.6) Group 0.682
12 months 18 10.7 (5.6 – 16.3) 24 14.1 (7.2 – 23.3) 21 16.7 (6.5 – 27.3) Interaction 0.083
Systolic blood pressure (mmHg)
Baseline 37 126 ± 16 39 123 ± 16 38 124 ± 16 Time 0.002
3 months 27 125 ± 12 30 120 ± 16 26 116 ± 12 Group 0.673
12 months 16 120 ± 11 23 128 ± 17 20 120 ± 13 Interaction 0.118
Diastolic blood pressure (mmHg)
Baseline 37 74 ± 10 39 72 ± 9 38 72 ± 9 Time 0.079
3 months 27 74 ± 9 30 72 ± 9 26 70 ± 8 Group 0.990
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Table 3 Body mass index, % body fat and clinical assessments at baseline, 3 months and 12 months (Continued)
12 months 16 72 ± 7 23 77 ± 10 20 74 ± 9 Interaction 0.112
HOMA-IR
Baseline 37 1.6 ± 1.1 39 1.5 ± 0.7 39 1.7 ± 0.7 Time < 0.001
3 months 27 1.3 ± 0.7 29 1.5 ± 0.9 28 1.4 ± 0.5 Group 0.326
12 months 17 1.2 ± 0.5 24 1.2 ± 0.5 21 1.3 ± 0.5 Interaction 0.300
Omega-3 index (%)**
Baseline 36 4.0 ± 1.2 38 3.5 ± 1.1 39 3.6 ± 1.1 Time 0.240
3 months 26 3.6 ± 2.0 30 3.6 ± 1.2 28 4.5 ± 1.7 Group 0.009
12 months 15 3.7 ± 0.9 23 3.4 ± 1.0 21 4.4 ± 1.6 Interaction 0.116
Values are expressed as mean ± SD or median (interquartile range).
HOMA-IR, homeostasis model assessment of insulin resistance.
*Linear mixed model, significance at p = 0.05.
¶Leptin adjusted for body fat.
†p value based on five time points (0, 3, 6, 9 and 12 months).
#Body fat assessed by DEXA.
‡Ln transformed.
**Erythrocyte[EPA + DHA]/[total fatty acids] × 100%.
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Under free living conditions, advice emphasising 2 fatty
fish meals a week did not enhance weight loss achieved
through low calorie dietary advice alone. The addition of
equivalent amounts of LCn3PUFA supplements slightly
increased LCn3PUFA status but did not influence weight
loss. The required energy deficit appeared met by the
total diet in all treatment groups, making it difficult to
attribute effects to advice on fish consumption, even if
supplemented with their key nutrients (LCn3PUFA).
From a nutrient perspective, our results are consistent
with other shorter term trials [11,12], but possibly for
different reasons. The target LCn3PUFA intake was the
Nutrient Reference Value for Australia and New Zealand
of about 600 mg [31]. The higher biomarker status
in the supplemented group suggested that supple-
ments may assure better LCn3PUFA intakes than
advice to consume fish, but this did not enhance
weight loss. It may be that higher doses are required,
although weight loss still was still achieved regardless
of supplementation.
Factors that may have affected results, such as
accounting for the n-6:n-3 ratio [32] did not change the
outcomes. We used a similar approach to supplementa-
tion as other studies testing effects of dietary LCn3PUFA
in ranges consumed in most populations (< 2 g/day) and
using an olive oil placebo [33]. Our results were con-
sistent with one of our previous trials [29], and while a
similar study showed greater improvements in disease
risk factors than ours [15], our study was longer
(12 months vs. 24 weeks) and our sample was not as
overweight, appeared to have lower levels of risk, and
our target intake of LCn3PUFA was lower (0.42 g EPA +
0.21 g DHA vs. 1.3 g EPA + 2.9 g DHA). We acknowledgethat low concentrations of erythrocyte EPA and DHA
have been linked with a number of negative health effects
[34] but this is a separate issue to weight loss in a low cal-
orie dietary content.
The dietary advice was based on nutrient-rich core
foods: vegetables, wholegrain cereals, fruits, lean meats
and low fat dairy foods, and we controlled for advice on
the total diet. Nevertheless, our results remained
congruent with a similar study applying a more liberal
ad libitum dietary advice strategy [12]. The considerable
variation in fish intakes, demonstrated the difficulty in
sustaining levels of fish consumption. The magnitude of
effect of the intervention was good, similar to that of a
12 months multicentre trial comparing different dietary
advice strategies [4]. Both studies showed no difference
in weight loss between diet advice groups with a lack of
compliance to actual dietary prescriptions. These studies
confirm that dietary energy intake is the main factor in
weight loss, but at the same time, the intention to treat
analysis provides evidence for the effects of the dietary
advice strategy.
As demonstrated in previous research [4], weight loss
in our study was associated with significant improve-
ments in a wide range of cardiovascular disease risk
factors. In the sample as a whole, we observed sig-
nificant reductions in systolic blood pressure, glucose,
insulin, and insulin resistance. Triglycerides were not
significantly reduced, but this was consistent with other
findings [15]. The drop in leptin levels across the sample
was congruent with reduced energy intakes, as would be
expected [35] and did not differ by treatment.
There were limitations to the study. As a feature of
long term ‘free living’ weight loss trials [15], the attrition
rate is disappointing, although the level was within the
Table 4 Reported daily energy, macronutrient and fibre intakes at baseline, 3 months and 12 months
Variable Control Fish Fish + S Difference between groups
n Value n Value n Value Effect p value*
Energy (kJ)
Baseline 39 9230 ± 2930 39 10190 ± 3970 40 10480 ± 3320 Time < 0.001
3 months 29 6600 ± 1510 29 6640 ± 1550 28 6350 ± 1240 Group 0.581
12 months 18 7330 ± 1750 25 6760 ± 1750 21 6700 ± 1490 Interaction 0.185
%E from protein
Baseline 39 19.5 ± 3.5 39 17.8 ± 3.2 40 18.1 ± 3.1 Time < 0.001
3 months 29 23.1 ± 4.1 29 22.4 ± 3.2 28 21.9 ± 2.7 Group 0.075
12 months 18 22.5 ± 3.9 25 21.2 ± 3.8 21 21.6 ± 3.2 Interaction 0.833
%E from fat
Baseline 39 32.4 ± 5.3 39 35.5 ± 5.9 40 34.9 ± 6.5 Time < 0.001
3 months 29 25.0 ± 6.2 29 27.0 ± 6.3 28 24.9 ± 4.3 Group 0.015
12 months 18 24.4 ± 5.6 25 29.1 ± 7.1 21 26.9 ± 5.8 Interaction 0.366
%E from saturated fat
Baseline 39 12.2 ± 3.0 39 12.7 ± 3.0 40 13.0 ± 4.0 Time < 0.001
3 months 29 8.1 ± 2.2 29 8.0 ± 2.2 28 7.6 ± 1.6 Group 0.800
12 months 18 8.5 ± 2.9 25 8.7 ± 2.7 21 8.6 ± 2.7 Interaction 0.727
%E from polyunsaturated fats
Baseline 39 5.2 ± 1.9 39 13.9 ± 3.1 40 13.6 ± 3.5 Time 0.570
3 months 29 4.4 ± 2.1 29 9.6 ± 2.5 28 9.3 ± 2.2 Group < 0.001
12 months 18 3.9 ± 1.1 25 11.3 ± 3.8 21 9.9 ± 3.1 Interaction 0.153
%E from monounsaturated fats
Baseline 39 12.0 ± 2.5 39 13.9 ± 3.1 40 13.6 ± 3.5 Time < 0.001
3 months 29 9.8 ± 3.3 29 9.6 ± 2.5 28 9.3 ± 2.2 Group 0.075
12 months 18 9.3 ± 2.5 25 11.3 ± 3.8 21 9.9 ± 3.0 Interaction 0.039
P:S ratio
Baseline 39 0.47 ± 0.24 39 0.50 ± 0.22 40 0.45 ± 0.19 Time < 0.001
3 months 29 0.58 ± 0.31 29 0.88 ± 0.45 28 0.72 ± 0.29 Group 0.007
12 months 18 0.50 ± 0.21 25 0.78 ± 0.59 21 0.73 ± 0.42 Interaction 0.061
Long chain n-3 polyunsaturated fatty acids (mg)†‡
Baseline 39 292 (195 – 760) 39 310 (198 – 446) 40 310 (167 – 474) Time 0.085
3 months 29 314 (178 – 456) 29 430 (219 – 917) 28 512 (272 – 706) Group 0.595
12 months 18 393 (195 – 521) 25 421 (129 – 675) 21 355 (178 – 815) Interaction 0.034
%E from carbohydrates
Baseline 39 41.5 ± 6.0 39 40.8 ± 6.1 40 43.4 ± 6.8 Time < 0.001
3 months 29 43.2 ± 10.9 29 44.7 ± 7.3 28 47.8 ± 5.5 Group 0.026
12 months 18 45.6 ± 6.0 25 43.4 ± 6.6 21 46.1 ± 4.9 Interaction 0.457
%E from alcohol
Baseline 39 4.9 ± 5.2 39 4.3 ± 4.3 40 2.3 ± 3.4 Time 0.611
3 months 29 4.8 ± 4.8 29 3.5 ± 3.8 28 2.9 ± 4.3 Group 0.159
12 months 18 5.4 ± 6.0 25 4.0 ± 5.0 21 3.0 ± 3.9 Interaction 0.218
Dietary cholesterol (mg)
Baseline 39 308 ± 135 39 322 ± 222 40 312 ± 113 Time < 0.001
3 months 29 213 ± 68 29 211 ± 64 28 191 ± 64 Group 0.827
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Table 4 Reported daily energy, macronutrient and fibre intakes at baseline, 3 months and 12 months (Continued)
12 months 18 242 ± 89 25 191 ± 63 21 209 ± 73 Interaction 0.885
Dietary fibre (g)
Baseline 39 25.7 ± 8.4 39 28.5 ± 9.4 40 28.6 ± 12.4 Time 0.008
3 months 29 23.9 ± 6.1 29 25.6 ± 5.9 28 26.1 ± 4.9 Group 0.535
12 months 18 25.2 ± 5.8 25 25.1 ± 6.5 21 25.3 ± 5.7 Interaction 0.855
Values are expressed as mean ± SD or median (interquartile range).
P:S ratio, polyunsaturated fatty acid to saturated fatty acid ratio.
*Linear mixed model, significance at p = 0.05.
†Ln transformed.
‡LC n-3 includes: 20:3n3 (eicosatrienoic acid), 20:5n3 (eicosapentaenoic acid), 22:5n3 (docosapentaenoic acid) and 22:6n3 (docosahexaenoic acid). Dietary data did
not include supplementation.
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istical analyses and while we acknowledge some limita-
tions [36] to the BOCF and LOCF methods, these are the
most commonly used in the weight loss RCT literature
[15]. The assumption that those who lost more weight are
more likely to complete is also considered in the analysis.
We saw little influence of attrition on results, drawing
conclusions from the intention to treat analysis vs. com-
pleters only analysis, and between the characteristics of
completers vs. dropouts.
The hypothesised effect was a difference in favour of the
treatment group (fish emphasis) of a weight loss of 2.1 kg
greater than the control (no fish emphasis). The results
show that the confidence intervals for the between group
differences in the completers do not include this value. In
addition, the difference between the Control and Fish arm
(−1.6 kg, 95% CI −5.1,1.8 in favour of control) in the com-
pleters did not support the alternate hypothesis that
emphasising fish in the dietary advice has a greater weight
loss effect. This was still the case with the Control and
Fish + Supps (−2.7 kg 95% CI-6.4,0.9 kg) where we had
enhanced the advice with fish oil supplements. The upper
CI of both intervention arms shows a value that is not
statistically significant. (Additional file 1: supplementary
Tables S1 and S2 show similar lack of differences between
completers for change in dietary intake and other out-
comes at 12 months). A greater weight loss of 0.9 or 1.8 kg
in the treatment groups compared with the control may be
too small to be considered clinically relevant after 12 mo.
Future studies could use our results to estimate sample
sizes for equivalence or use the variance estimates to
determine difference needed for effect.
A major strength of our study was that the trial
extended to 12 months follow up [37], with regular
monitoring and continual engagement with the partici-
pants to motivate sustained dietary change. Compliance
with the supplement regimen was confirmed with
erythrocyte fatty acid concentrations. By basing dietary
advice in all groups on core foods, we addressed the lack
of dietary controls and variation in food sources which
often hampers studies of dietary fat [38].Conclusions
Advice to consume 2 fish meals per week did not appear
to enhance the effects on weight loss of a healthy low
calorie diet, however further studies with greater power
may be required to make this conclusion. In considering
the relative roles of nutrients, food and whole diets [3],
we conclude that the whole diet may the most tangible
nutritional parameter in deriving evidence for food
effects in weight loss studies.
Additional file
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